Figure 1.
Association between severity, and time-to-onset of CRS with that of ICANS after CAR T-cell therapy. Kinetics of CRS (A) and ICANS (B) in each patient in the study cohort during 14 days of CAR T-cell infusion, colors indicate the grade of toxicity recorded each day. NA indicates that either the patient was discharged, assessment was declined, or grading could not be performed. (C) Maximum grade of ICANS and CRS recorded for patients after CAR T-cell infusion, color indicates the percentage of the cohort affected. (D) Associations between the outcomes (grade and time-to-onset) of CRS with those of ICANS (n = 41 patients). (E) Workflow of metabolomics platform and analysis.

Association between severity, and time-to-onset of CRS with that of ICANS after CAR T-cell therapy. Kinetics of CRS (A) and ICANS (B) in each patient in the study cohort during 14 days of CAR T-cell infusion, colors indicate the grade of toxicity recorded each day. NA indicates that either the patient was discharged, assessment was declined, or grading could not be performed. (C) Maximum grade of ICANS and CRS recorded for patients after CAR T-cell infusion, color indicates the percentage of the cohort affected. (D) Associations between the outcomes (grade and time-to-onset) of CRS with those of ICANS (n = 41 patients). (E) Workflow of metabolomics platform and analysis.

Close Modal

or Create an Account

Close Modal
Close Modal